The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Equine Influenza Vaccine Market Research Report 2025
Synopsis
Equine influenza (horse flu) is the disease caused by strains of influenza A that are enzootic in horse species. Equine influenza occurs globally, previously caused by two main strains of virus: equine-1 (H7N7) and equine-2 (H3N8). The World Organisation for Animal Health now considers H7N7 strains likely to be extinct since these strains have not been isolated for over 20 years. Predominant international circulating H3N8 strains are Florida sublineage of the American lineage; clade 1 predominates in the Americas and clade 2 in Europe. (Elton and Cullinane, 2013; Paillot, 2014; Slater et al., 2013[4]). The disease has a nearly 100% infection rate in an unvaccinated horse population with no prior exposure to the virus.
The global Equine Influenza Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Equine Influenza Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Equine Influenza Vaccine.
Report Scope
The Equine Influenza Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Equine Influenza Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Equine Influenza Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Zoetis
Merck Animal Health
Boehringer Ingelheim Vetmedica
Segment by Type
Liquid
Powder
Segment by Application
Home
Pet Clinic
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Equine Influenza Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Equine Influenza Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Equine influenza (horse flu) is the disease caused by strains of influenza A that are enzootic in horse species. Equine influenza occurs globally, previously caused by two main strains of virus: equine-1 (H7N7) and equine-2 (H3N8). The World Organisation for Animal Health now considers H7N7 strains likely to be extinct since these strains have not been isolated for over 20 years. Predominant international circulating H3N8 strains are Florida sublineage of the American lineage; clade 1 predominates in the Americas and clade 2 in Europe. (Elton and Cullinane, 2013; Paillot, 2014; Slater et al., 2013[4]). The disease has a nearly 100% infection rate in an unvaccinated horse population with no prior exposure to the virus.
The global Equine Influenza Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Equine Influenza Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Equine Influenza Vaccine.
Report Scope
The Equine Influenza Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Equine Influenza Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Equine Influenza Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Zoetis
Merck Animal Health
Boehringer Ingelheim Vetmedica
Segment by Type
Liquid
Powder
Segment by Application
Home
Pet Clinic
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Equine Influenza Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Equine Influenza Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Equine Influenza Vaccine Market Overview
1.1 Product Overview and Scope of Equine Influenza Vaccine
1.2 Equine Influenza Vaccine Segment by Type
1.2.1 Global Equine Influenza Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Liquid
1.2.3 Powder
1.3 Equine Influenza Vaccine Segment by Application
1.3.1 Global Equine Influenza Vaccine Market Value by Application: (2024-2030)
1.3.2 Home
1.3.3 Pet Clinic
1.3.4 Others
1.4 Global Equine Influenza Vaccine Market Size Estimates and Forecasts
1.4.1 Global Equine Influenza Vaccine Revenue 2019-2030
1.4.2 Global Equine Influenza Vaccine Sales 2019-2030
1.4.3 Global Equine Influenza Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Equine Influenza Vaccine Market Competition by Manufacturers
2.1 Global Equine Influenza Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Equine Influenza Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Equine Influenza Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Equine Influenza Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Equine Influenza Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Equine Influenza Vaccine, Product Type & Application
2.7 Equine Influenza Vaccine Market Competitive Situation and Trends
2.7.1 Equine Influenza Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Equine Influenza Vaccine Players Market Share by Revenue
2.7.3 Global Equine Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Equine Influenza Vaccine Retrospective Market Scenario by Region
3.1 Global Equine Influenza Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Equine Influenza Vaccine Global Equine Influenza Vaccine Sales by Region: 2019-2030
3.2.1 Global Equine Influenza Vaccine Sales by Region: 2019-2024
3.2.2 Global Equine Influenza Vaccine Sales by Region: 2025-2030
3.3 Global Equine Influenza Vaccine Global Equine Influenza Vaccine Revenue by Region: 2019-2030
3.3.1 Global Equine Influenza Vaccine Revenue by Region: 2019-2024
3.3.2 Global Equine Influenza Vaccine Revenue by Region: 2025-2030
3.4 North America Equine Influenza Vaccine Market Facts & Figures by Country
3.4.1 North America Equine Influenza Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Equine Influenza Vaccine Sales by Country (2019-2030)
3.4.3 North America Equine Influenza Vaccine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Equine Influenza Vaccine Market Facts & Figures by Country
3.5.1 Europe Equine Influenza Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Equine Influenza Vaccine Sales by Country (2019-2030)
3.5.3 Europe Equine Influenza Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Equine Influenza Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Equine Influenza Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Equine Influenza Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Equine Influenza Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Equine Influenza Vaccine Market Facts & Figures by Country
3.7.1 Latin America Equine Influenza Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Equine Influenza Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Equine Influenza Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Equine Influenza Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Equine Influenza Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Equine Influenza Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Equine Influenza Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Equine Influenza Vaccine Sales by Type (2019-2030)
4.1.1 Global Equine Influenza Vaccine Sales by Type (2019-2024)
4.1.2 Global Equine Influenza Vaccine Sales by Type (2025-2030)
4.1.3 Global Equine Influenza Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Equine Influenza Vaccine Revenue by Type (2019-2030)
4.2.1 Global Equine Influenza Vaccine Revenue by Type (2019-2024)
4.2.2 Global Equine Influenza Vaccine Revenue by Type (2025-2030)
4.2.3 Global Equine Influenza Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Equine Influenza Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Equine Influenza Vaccine Sales by Application (2019-2030)
5.1.1 Global Equine Influenza Vaccine Sales by Application (2019-2024)
5.1.2 Global Equine Influenza Vaccine Sales by Application (2025-2030)
5.1.3 Global Equine Influenza Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Equine Influenza Vaccine Revenue by Application (2019-2030)
5.2.1 Global Equine Influenza Vaccine Revenue by Application (2019-2024)
5.2.2 Global Equine Influenza Vaccine Revenue by Application (2025-2030)
5.2.3 Global Equine Influenza Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Equine Influenza Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Zoetis
6.1.1 Zoetis Corporation Information
6.1.2 Zoetis Description and Business Overview
6.1.3 Zoetis Equine Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Zoetis Equine Influenza Vaccine Product Portfolio
6.1.5 Zoetis Recent Developments/Updates
6.2 Merck Animal Health
6.2.1 Merck Animal Health Corporation Information
6.2.2 Merck Animal Health Description and Business Overview
6.2.3 Merck Animal Health Equine Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck Animal Health Equine Influenza Vaccine Product Portfolio
6.2.5 Merck Animal Health Recent Developments/Updates
6.3 Boehringer Ingelheim Vetmedica
6.3.1 Boehringer Ingelheim Vetmedica Corporation Information
6.3.2 Boehringer Ingelheim Vetmedica Description and Business Overview
6.3.3 Boehringer Ingelheim Vetmedica Equine Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Boehringer Ingelheim Vetmedica Equine Influenza Vaccine Product Portfolio
6.3.5 Boehringer Ingelheim Vetmedica Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Equine Influenza Vaccine Industry Chain Analysis
7.2 Equine Influenza Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Equine Influenza Vaccine Production Mode & Process
7.4 Equine Influenza Vaccine Sales and Marketing
7.4.1 Equine Influenza Vaccine Sales Channels
7.4.2 Equine Influenza Vaccine Distributors
7.5 Equine Influenza Vaccine Customers
8 Equine Influenza Vaccine Market Dynamics
8.1 Equine Influenza Vaccine Industry Trends
8.2 Equine Influenza Vaccine Market Drivers
8.3 Equine Influenza Vaccine Market Challenges
8.4 Equine Influenza Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Equine Influenza Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Equine Influenza Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Equine Influenza Vaccine Market Competitive Situation by Manufacturers in 2023
Table 4. Global Equine Influenza Vaccine Sales (K Doses) of Key Manufacturers (2019-2024)
Table 5. Global Equine Influenza Vaccine Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Equine Influenza Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Equine Influenza Vaccine Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Equine Influenza Vaccine Average Price (USD/Dose) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Equine Influenza Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Equine Influenza Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Equine Influenza Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Equine Influenza Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Equine Influenza Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Equine Influenza Vaccine as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Equine Influenza Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Equine Influenza Vaccine Sales by Region (2019-2024) & (K Doses)
Table 18. Global Equine Influenza Vaccine Sales Market Share by Region (2019-2024)
Table 19. Global Equine Influenza Vaccine Sales by Region (2025-2030) & (K Doses)
Table 20. Global Equine Influenza Vaccine Sales Market Share by Region (2025-2030)
Table 21. Global Equine Influenza Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Equine Influenza Vaccine Revenue Market Share by Region (2019-2024)
Table 23. Global Equine Influenza Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Equine Influenza Vaccine Revenue Market Share by Region (2025-2030)
Table 25. North America Equine Influenza Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Equine Influenza Vaccine Sales by Country (2019-2024) & (K Doses)
Table 27. North America Equine Influenza Vaccine Sales by Country (2025-2030) & (K Doses)
Table 28. North America Equine Influenza Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Equine Influenza Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Equine Influenza Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Equine Influenza Vaccine Sales by Country (2019-2024) & (K Doses)
Table 32. Europe Equine Influenza Vaccine Sales by Country (2025-2030) & (K Doses)
Table 33. Europe Equine Influenza Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Equine Influenza Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Equine Influenza Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Equine Influenza Vaccine Sales by Region (2019-2024) & (K Doses)
Table 37. Asia Pacific Equine Influenza Vaccine Sales by Region (2025-2030) & (K Doses)
Table 38. Asia Pacific Equine Influenza Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Equine Influenza Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Equine Influenza Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Equine Influenza Vaccine Sales by Country (2019-2024) & (K Doses)
Table 42. Latin America Equine Influenza Vaccine Sales by Country (2025-2030) & (K Doses)
Table 43. Latin America Equine Influenza Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Equine Influenza Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Equine Influenza Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Equine Influenza Vaccine Sales by Country (2019-2024) & (K Doses)
Table 47. Middle East & Africa Equine Influenza Vaccine Sales by Country (2025-2030) & (K Doses)
Table 48. Middle East & Africa Equine Influenza Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Equine Influenza Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Equine Influenza Vaccine Sales (K Doses) by Type (2019-2024)
Table 51. Global Equine Influenza Vaccine Sales (K Doses) by Type (2025-2030)
Table 52. Global Equine Influenza Vaccine Sales Market Share by Type (2019-2024)
Table 53. Global Equine Influenza Vaccine Sales Market Share by Type (2025-2030)
Table 54. Global Equine Influenza Vaccine Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Equine Influenza Vaccine Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Equine Influenza Vaccine Revenue Market Share by Type (2019-2024)
Table 57. Global Equine Influenza Vaccine Revenue Market Share by Type (2025-2030)
Table 58. Global Equine Influenza Vaccine Price (USD/Dose) by Type (2019-2024)
Table 59. Global Equine Influenza Vaccine Price (USD/Dose) by Type (2025-2030)
Table 60. Global Equine Influenza Vaccine Sales (K Doses) by Application (2019-2024)
Table 61. Global Equine Influenza Vaccine Sales (K Doses) by Application (2025-2030)
Table 62. Global Equine Influenza Vaccine Sales Market Share by Application (2019-2024)
Table 63. Global Equine Influenza Vaccine Sales Market Share by Application (2025-2030)
Table 64. Global Equine Influenza Vaccine Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Equine Influenza Vaccine Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Equine Influenza Vaccine Revenue Market Share by Application (2019-2024)
Table 67. Global Equine Influenza Vaccine Revenue Market Share by Application (2025-2030)
Table 68. Global Equine Influenza Vaccine Price (USD/Dose) by Application (2019-2024)
Table 69. Global Equine Influenza Vaccine Price (USD/Dose) by Application (2025-2030)
Table 70. Zoetis Corporation Information
Table 71. Zoetis Description and Business Overview
Table 72. Zoetis Equine Influenza Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 73. Zoetis Equine Influenza Vaccine Product
Table 74. Zoetis Recent Developments/Updates
Table 75. Merck Animal Health Corporation Information
Table 76. Merck Animal Health Description and Business Overview
Table 77. Merck Animal Health Equine Influenza Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 78. Merck Animal Health Equine Influenza Vaccine Product
Table 79. Merck Animal Health Recent Developments/Updates
Table 80. Boehringer Ingelheim Vetmedica Corporation Information
Table 81. Boehringer Ingelheim Vetmedica Description and Business Overview
Table 82. Boehringer Ingelheim Vetmedica Equine Influenza Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 83. Boehringer Ingelheim Vetmedica Equine Influenza Vaccine Product
Table 84. Boehringer Ingelheim Vetmedica Recent Developments/Updates
Table 85. Key Raw Materials Lists
Table 86. Raw Materials Key Suppliers Lists
Table 87. Equine Influenza Vaccine Distributors List
Table 88. Equine Influenza Vaccine Customers List
Table 89. Equine Influenza Vaccine Market Trends
Table 90. Equine Influenza Vaccine Market Drivers
Table 91. Equine Influenza Vaccine Market Challenges
Table 92. Equine Influenza Vaccine Market Restraints
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Equine Influenza Vaccine
Figure 2. Global Equine Influenza Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Equine Influenza Vaccine Market Share by Type in 2023 & 2030
Figure 4. Liquid Product Picture
Figure 5. Powder Product Picture
Figure 6. Global Equine Influenza Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Equine Influenza Vaccine Market Share by Application in 2023 & 2030
Figure 8. Home
Figure 9. Pet Clinic
Figure 10. Others
Figure 11. Global Equine Influenza Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Equine Influenza Vaccine Market Size (2019-2030) & (US$ Million)
Figure 13. Global Equine Influenza Vaccine Sales (2019-2030) & (K Doses)
Figure 14. Global Equine Influenza Vaccine Average Price (USD/Dose) & (2019-2030)
Figure 15. Equine Influenza Vaccine Report Years Considered
Figure 16. Equine Influenza Vaccine Sales Share by Manufacturers in 2023
Figure 17. Global Equine Influenza Vaccine Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Equine Influenza Vaccine Players: Market Share by Revenue in 2023
Figure 19. Equine Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Equine Influenza Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Equine Influenza Vaccine Sales Market Share by Country (2019-2030)
Figure 22. North America Equine Influenza Vaccine Revenue Market Share by Country (2019-2030)
Figure 23. U.S. Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Equine Influenza Vaccine Sales Market Share by Country (2019-2030)
Figure 26. Europe Equine Influenza Vaccine Revenue Market Share by Country (2019-2030)
Figure 27. Germany Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Equine Influenza Vaccine Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Equine Influenza Vaccine Revenue Market Share by Region (2019-2030)
Figure 34. China Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Taiwan Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Indonesia Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Thailand Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Malaysia Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Philippines Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Latin America Equine Influenza Vaccine Sales Market Share by Country (2019-2030)
Figure 45. Latin America Equine Influenza Vaccine Revenue Market Share by Country (2019-2030)
Figure 46. Mexico Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Brazil Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Argentina Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Equine Influenza Vaccine Sales Market Share by Country (2019-2030)
Figure 50. Middle East & Africa Equine Influenza Vaccine Revenue Market Share by Country (2019-2030)
Figure 51. Turkey Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. U.A.E Equine Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Global Sales Market Share of Equine Influenza Vaccine by Type (2019-2030)
Figure 55. Global Revenue Market Share of Equine Influenza Vaccine by Type (2019-2030)
Figure 56. Global Equine Influenza Vaccine Price (USD/Dose) by Type (2019-2030)
Figure 57. Global Sales Market Share of Equine Influenza Vaccine by Application (2019-2030)
Figure 58. Global Revenue Market Share of Equine Influenza Vaccine by Application (2019-2030)
Figure 59. Global Equine Influenza Vaccine Price (USD/Dose) by Application (2019-2030)
Figure 60. Equine Influenza Vaccine Value Chain
Figure 61. Equine Influenza Vaccine Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
